A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy

Prevention of Delayed Nausea: A University of Rochester Cancer Center Community Clinical Oncology Program Study of Patients Receiving Chemotherapy

(2012) Joseph A. Roscoe et al.   JOURNAL OF CLINICAL ONCOLOGY

Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update

(2011) Ethan Basch et al.   JOURNAL OF CLINICAL ONCOLOGY

Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference

(2010) F. Roila et al.   ANNALS OF ONCOLOGY

Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy

(2009) Paul J. Hesketh et al.   SUPPORTIVE CARE IN CANCER

Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study

(2009) Bernardo L. Rapoport et al.   SUPPORTIVE CARE IN CANCER

Chemotherapy-Induced Nausea and Vomiting

(2008) Paul J. Hesketh   NEW ENGLAND JOURNAL OF MEDICINE